BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
0.203
+0.001 (0.50%)
At close: Dec 20, 2024, 4:00 PM
0.208
+0.005 (2.66%)
After-hours: Dec 20, 2024, 6:31 PM EST
BioLineRx Employees
BioLineRx had 79 employees as of December 31, 2023. The number of employees increased by 30 or 61.22% compared to the previous year.
Employees
79
Change (1Y)
30
Growth (1Y)
61.22%
Revenue / Employee
$278,367
Profits / Employee
-$252,127
Market Cap
19.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Concord Medical Services Holdings | 727 |
Retractable Technologies | 151 |
Bolt Biotherapeutics | 100 |
Affimed | 76 |
Senti Biosciences | 48 |
Palatin Technologies | 30 |
Bullfrog AI | 11 |
Alterity Therapeutics | 10 |
BLRX News
- 26 days ago - BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value - PRNewsWire
- 4 weeks ago - BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. - PRNewsWire
- 4 weeks ago - BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - PRNewsWire
- 6 weeks ago - BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 - PRNewsWire
- 2 months ago - BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide - PRNewsWire
- 3 months ago - BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection - PRNewsWire
- 4 months ago - BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript - Seeking Alpha